Literature DB >> 33241780

Lassa Fever among Children in Eastern Province, Sierra Leone: A 7-year Retrospective Analysis (2012-2018).

Robert J Samuels1,2, Troy D Moon1, Joseph R Starnes1, Foday Alhasan2, Michael Gbakie2, Augustine Goba2, Veronica Koroma2, Mambu Momoh2, John Demby Sandi2, Robert F Garry2,3, Emily J Engel4, Jeffrey G Shaffer5, John S Schieffelin2,4, Donald S Grant2,6.   

Abstract

Pediatric Lassa fever (LF) usually presents as a nonspecific febrile illness, similar to other endemic diseases in countries like Sierra Leone, where LF is considered to be hyperendemic. The nonspecificity of presentation and lack of research have made it difficult to fully understand best practices for pediatric management. We aim to describe clinical characteristics of hospitalized pediatric patients suspected or diagnosed with LF and assess factors associated with hospital outcomes among those with LF antigen-positive results. We conducted a 7-year retrospective cohort study using routine data for all children younger than 18 years admitted at the Kenema Government Hospital's LF ward. A total of 292 children with suspected or confirmed LF were analyzed. Overall, mortality was high (21%). Children with antigen-positive results had a high case fatality rate of 63% (P < 0.01). In univariate analyses, children who presented with unexplained bleeding (odds ratio [OR]: 3.58; 95% CI: 1.08-11.86; P = 0.040) and confusion (altered sensorium) (OR: 5.37; 95% CI: 1.34-21.48; P = 0.020) had increased odds of death. Abnormal serum levels of alanine aminotransferase (P = 0.001), creatinine (P = 0.004), and potassium (P = 0.003) were associated with increased likelihood of death in these children. Treatment with ribavirin was not significantly associated with survival (P = 0.916). Our findings provide insights into current pediatric LF clinical presentation and management. More evidence-based, high-quality research in creating predictive algorithms of antigen-positivity and hospital outcomes is needed in the management of pediatric LF.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33241780      PMCID: PMC7866338          DOI: 10.4269/ajtmh.20-0773

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.

Authors:  Laura Merson; Josephine Bourner; Sulaiman Jalloh; Astrid Erber; Alex Paddy Salam; Antoine Flahault; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2021-09-21

Review 2.  Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1.

Authors:  Hung-Yuan Cheng; Clare E French; Alex P Salam; Sarah Dawson; Alexandra McAleenan; Luke A McGuinness; Jelena Savović; Peter W Horby; Jonathan A C Sterne
Journal:  Emerg Infect Dis       Date:  2022-08       Impact factor: 16.126

3.  Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012-2019.

Authors:  Jeffrey G Shaffer; John S Schieffelin; Mambu Momoh; Augustine Goba; Lansana Kanneh; Foday Alhasan; Michael Gbakie; Emily J Engel; Nell G Bond; Jessica N Hartnett; Diana K S Nelson; Duane J Bush; Matthew L Boisen; Megan L Heinrich; Megan M Rowland; Luis M Branco; Robert J Samuels; Robert F Garry; Donald S Grant
Journal:  Microorganisms       Date:  2021-03-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.